Skip to content
TrialMatch
Sign up
Recruiting

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.

Condition
Lung Cancer (NSCLC), Lymph Node Dissection
Tested
Selective lymph node dissection
Sponsor
Fudan University

Who can join

Age
18 to 80 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 12

  • Minimum age: 18 years
  • Maximum age: 80 years
  • Study condition: Lung Cancer (NSCLC), Lymph Node Dissection
  • Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
  • Age 18-80 years at time of signing informed consent (including threshold);
  • ECOG score 0 or 1;
  • No previous surgery for lung cancer;
  • Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
  • Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
  • The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
  • Patients with clinical stage T1N0M0 surgically resectable;
  • Primary treatment without radiotherapy or chemotherapy.

Exclusion 5

  • T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm;
  • Inability to perform complete surgical resection;
  • cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
  • Previous surgery for lung cancer;
  • Patients who have received radiotherapy or chemotherapy for non-primary treatment.

Where

1 site, 1 recruiting

Fudan University Shanghai Cancer Center

Shanghai, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.